BACKGROUND: Fraction of exhaled nitrous oxide (FeNO) is a known marker of airway inflammation and a topic of recent investigation for asthma control in children. OBJECTIVE: To investigate the relationship among FeNO and bronchodilator response measured by spirometry and types of inhaled corticosteroids (ICS). METHODS: A one-year review of children tested with spirometry and FeNO in a regional pediatric asthma centre was conducted. RESULTS: A total of 183 children were included (mean [± SD] age 12.8 ± 2.8 years). Fluticasone was used most commonly (n=66 [36.1%]), followed by ciclesonide (n=50 [27.3%]). Most children (n=73 [39.9%]) had moderate persistent asthma. Increased FeNO was associated with percent change in forced expiratory volume in 1 s (FEV1) after bronchodilator adjusted for allergic rhinitis, parental smoking and ICS type (B=0.08 [95% CI 0.04 to 0.12]; P<0.001). Similarly, FeNO was associated with percent change in forced expiratory flow at 25% to 75% of the pulmonary volume (FEF25-75) after bronchodilator adjusted for parental smoking and ICS type (B=0.13 [95% CI 0.01 to 0.24]; P=0.03). FeNO accounted for only 16% and 9% of the variability in FEV1 and FEF25-75, respectively. Mean-adjusted FeNO was lowest in fluticasone users compared with no ICS (mean difference 18.6 parts per billion [ppb] [95% CI 1.0 to 36.2]) and there was no difference in adjusted FeNO level between ciclesonide and no ICS (5.9 ppb [95% CI -9.0 to 20.8]). CONCLUSION: FeNO levels correlated with bronchodilator response in a regional pediatric asthma centre. However, FeNO accounted for only 16% and 9% of the variability in FEV1 and FEF25-75, respectively. Mean adjusted FeNO varied according to ICS type, suggesting a difference in relative efficacy between ICS beyond their dose equivalents.
BACKGROUND: Fraction of exhaled nitrous oxide (FeNO) is a known marker of airway inflammation and a topic of recent investigation for asthma control in children. OBJECTIVE: To investigate the relationship among FeNO and bronchodilator response measured by spirometry and types of inhaled corticosteroids (ICS). METHODS: A one-year review of children tested with spirometry and FeNO in a regional pediatric asthma centre was conducted. RESULTS: A total of 183 children were included (mean [± SD] age 12.8 ± 2.8 years). Fluticasone was used most commonly (n=66 [36.1%]), followed by ciclesonide (n=50 [27.3%]). Most children (n=73 [39.9%]) had moderate persistent asthma. Increased FeNO was associated with percent change in forced expiratory volume in 1 s (FEV1) after bronchodilator adjusted for allergic rhinitis, parental smoking and ICS type (B=0.08 [95% CI 0.04 to 0.12]; P<0.001). Similarly, FeNO was associated with percent change in forced expiratory flow at 25% to 75% of the pulmonary volume (FEF25-75) after bronchodilator adjusted for parental smoking and ICS type (B=0.13 [95% CI 0.01 to 0.24]; P=0.03). FeNO accounted for only 16% and 9% of the variability in FEV1 and FEF25-75, respectively. Mean-adjusted FeNO was lowest in fluticasone users compared with no ICS (mean difference 18.6 parts per billion [ppb] [95% CI 1.0 to 36.2]) and there was no difference in adjusted FeNO level between ciclesonide and no ICS (5.9 ppb [95% CI -9.0 to 20.8]). CONCLUSION:FeNO levels correlated with bronchodilator response in a regional pediatric asthma centre. However, FeNO accounted for only 16% and 9% of the variability in FEV1 and FEF25-75, respectively. Mean adjusted FeNO varied according to ICS type, suggesting a difference in relative efficacy between ICS beyond their dose equivalents.
Authors: Andrew D Smith; Jan O Cowan; Sue Filsell; Chris McLachlan; Gabrielle Monti-Sheehan; Pamela Jackson; D Robin Taylor Journal: Am J Respir Crit Care Med Date: 2003-11-25 Impact factor: 21.405
Authors: M D Lougheed; C Lemière; S D Dell; F M Ducharme; J Mark Fitzgerald; R Leigh; C Licskai; B H Rowe; D Bowie; A Becker; Louis-Philippe Boulet Journal: Can Respir J Date: 2010 Jan-Feb Impact factor: 2.409
Authors: Margaret M Kelly; Richard Leigh; Lata Jayaram; Charlie H Goldsmith; Krishnan Parameswaran; Frederick E Hargreave Journal: J Allergy Clin Immunol Date: 2006-03-31 Impact factor: 10.793
Authors: Allan L Coates; Brian L Graham; Robin G McFadden; Colm McParland; Dilshad Moosa; Steeve Provencher; Jeremy Road Journal: Can Respir J Date: 2013 Jan-Feb Impact factor: 2.409
Authors: Edward M Erin; Angela S Zacharasiewicz; Grant C Nicholson; Andrew J Tan; Helen Neighbour; Renate Engelstätter; Michael Hellwig; Onn Min Kon; Peter J Barnes; Trevor T Hansel Journal: Chest Date: 2008-04-10 Impact factor: 9.410